In patients who develop a VTE on palbociclib, do you discontinue therapy or continue as long as the patient is receiving adequate anticoagulation therapy?

Thromboembolic events were seen in Paloma studies but the frequency was quite low and comparable with what would be expected to be associated with the presence of metastatic disease. Initially, there seemed to be a small increase in the patients taking palbociclib compared to the control arms. In the smaller phase 2 Paloma 1 study, the risk of pulmonary embolism was found to 4% in letrozole/palbociclib group and none in letrozole group. In the Paloma 3 trial, only 0.9% (N=3) of patients in the palbociclib/fulvestrant group had pulmonary embolism (none in the control arm). However, in the largest, phase 3 Paloma 2 study, pulmonary embolism was found in 0.9% of patients taking letrozole/palbociclib and 1.4% of patient's on letrozole/placebo a...